Phone: (713) 794-5625; Fax: (713) 794-5664
Stability of estrogen receptor status in breast carcinoma†
A comparison between primary and metastatic tumors with regard to disease course and intervening systemic therapy
Article first published online: 11 OCT 2010
Copyright © 2010 American Cancer Society
Volume 117, Issue 4, pages 705–713, 15 February 2011
How to Cite
Gong, Y., Han, E. Y., Guo, M., Pusztai, L. and Sneige, N. (2011), Stability of estrogen receptor status in breast carcinoma. Cancer, 117: 705–713. doi: 10.1002/cncr.25506
Presented in part at the 98th annual meeting of the United States and Canadian Academy of Pathology, Boston, MA, March 7-13, 2008, and in part at the 57th Annual Scientific Meeting of the American Society of Cytopathology, Denver, CO, November 13-17, 2009.
- Issue published online: 3 FEB 2011
- Article first published online: 11 OCT 2010
- Manuscript Accepted: 4 MAY 2010
- Manuscript Revised: 3 MAY 2010
- Manuscript Received: 5 APR 2010
- estrogen receptor;
The purposes of this study were to address a persistent controversy as to whether the ER status of a primary tumor remains stable during progression to metastasis and to evaluate the influence of disease course and prior systemic therapy on ER status.
Breast carcinomas from 227 women with known ER status in both primary tumor and paired metastasis were retrospectively reviewed. ER status was compared between primary and metastatic tumors with respect to metastatic site, interval between two ER assays, and intervening chemotherapy and endocrine therapy. Semiquantitative comparison of ER values was performed for 92 tumor pairs.
ER status agreed in 210 (92.5%) patients, including 147 positive and 63 negative. Of the 17 patients (7.5%) with discordant ER status, both negative to positive conversion (n = 7) and positive to negative conversion (n = 10) were observed. ER discordance was not significantly associated with metastatic site (locoregional vs distant), time interval between assays (<5 years vs. ≥5 years), or intervening chemotherapy and endocrine therapy. Semiquantitative levels of ER expression were similar between primary and metastatic tumors. In discordant cases, variations in testing methods and marginal scores were common.
ER status in breast carcinoma is generally stable during progression to metastasis. Preanalytical and analytical variability may contribute to discordance in some cases. Given the importance of ER status for clinical management, ER testing in metastatic breast carcinoma should be repeated, especially for patients whose clinical courses are not compatible with stated ER status. Cancer 2011. © 2010 American Cancer Society.